VERTEX PHARMACEUTICALS NASDAQ: VRTX
Background of Vertex Pharmaceuticals
- Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company, and it was one of the first biotech firms in history to use an explicit strategy of rational drug design instead of combinatorial chemistry.
- Joshua Boger and Kevin J. Kinsella established Vertex Pharmaceuticals, Inc. in 1989 and even during its early history, the company was at the forefront of the biotech revolution.
- Barry Werth detailed the beginnings of Vertex Pharmaceuticals, Inc. in his book “The Billion-Dollar Molecule”, published in 1994. It was further developed in 2014 with another book, “The Antidote: Inside the World of New Pharma”.
- By 2004, Vertex Pharmaceuticals, Inc.’s product portfolio focused on viral infections, inflammatory, and autoimmune disorders along with cancer.
- By 2009, Vertex Pharmaceuticals, Inc. had 1,800 employees, including 1,200 in the Boston area and by 2019, Vertex Pharmaceuticals, Inc. had more than 2,500 employees.
- Since its establishment, Vertex Pharmaceuticals, Inc. has developed several drugs and since 2011, Vertex Pharmaceuticals, Inc. has ranked among the top 15 best performing companies on the S&P 500. During this time, Vertex Pharmaceuticals, Inc. shares increased 250%.
- In 2014, Vertex Pharmaceuticals, Inc. moved from Cambridge, Massachusetts to Boston Massachusetts, taking residence in a building to the value of $800 million (11.6 billion ZAR). Located in South Boston, it marked the first time in the history of the company that all 1,200 Vertex Pharmaceuticals, Inc. employees in the Greater Boston area worked together.
- in 2019, the COO and interim CFO of Vertex Pharmaceuticals, Inc., Ian Smith, was terminated from his position as result of undisclosed personal behaviour which violated code of conduct rules established by the company.
- In mid-2019, Vertex Pharmaceuticals, Inc. announced the purchase of Exonics Therapeutics for up to $1 billion (14.6 billion ZAR) and collaborated with CRISPR Therapeutics. This boosted the development of treatments of Duchenne muscular dystrophy as well as Myotonic Dystrophy Type 1.
- In September 2019, Vertex Pharmaceuticals, Inc. announced the purchase of Semma Therapeutics for $950 million (13.8 million ZAR) in cash. Semma Therapeutics developed a small and implantable device which holds millions of replacement beta cells which allow glucose and insulin through without letting immune cells in.
- In April 2025, the former Chief Medical Officer, Reshma Kewalramani, became the President and Chief Executive Officer of Vertex Pharmaceuticals, Inc. while the former CEO and President took the role as Executive Chairman of the Board of Directors.
- Vertex Pharmaceuticals, Inc.’s product portfolio consist of a range of medicines including Ivacaftor, lumacaftor, and tezacaftor. There are also triple combination treatments as well as genetic therapies which is done in collaboration with other biotech and pharma companies such as CRISPR Therapeutics, Moderna, Arbor Biotechnologies, and several others.
- Today, Vertex Pharmaceuticals, Inc. is headquartered in South Boston while it also operates three research facilities in San Diego, California, and Milton Park, located near Oxford, England.
Vertex Pharmaceuticals Shares Growth Driver
- Vertex Pharmaceuticals, Inc. is a global biotechnology company which invests in scientific innovation to create medicines which are transformative for those who live with serious diseases.
- Vertex Pharmaceuticals, Inc. has multiple approved medicines which treat the underlying cause of cystic fibrosis (CF) and Vertex Pharmaceuticals, Inc. has several ongoing clinical and research programs in CF.
- Beyond CF, Vertex Pharmaceuticals, Inc. has a robust portfolio of investigational small molecule medicines to treat other diseases where there is deep insight into casual human biology, including pain, alpha1 antitrypsin deficiency as well as APOL1-mediated kidney diseases.
- Vertex Pharmaceuticals, Inc. is consistently expanding its portfolio of genetic and cell therapies for a range of diseases including sickle cell disease, beta thalassemia, type 1 diabetes mellitus, and Duchenne muscular dystrophy.
- Vertex Pharmaceuticals, Inc. is recognised as one of the top workplaces for employees, including 11 consecutive years on the Science magazine’s top Employers list.
- In addition to this, Vertex Pharmaceuticals, Inc. shows consistent innovation in medicinal developments and technologies along with strong financial performance.
- The second quarter of 2025 showed that Vertex Pharmaceuticals, Inc. achieved consistent, significant growth as well as strong business service, especially in the cystic fibrosis franchise.
- Vertex Pharmaceuticals, Inc. has secured reimbursement agreements for the triple combination in more than 15 countries outside of the United States, starting with expansions into younger age groups in the U.S, with approval in patients ranging from 6 to 11 years of age in the last month.
- These advancements have ensured that Vertex Pharmaceuticals, Inc. is poised to reach more patients in 2025 than was previously forecasted. Therefore, Vertex Pharmaceuticals, Inc. has raised its 2025 revenue guidance.
- Looking forward, Vertex Pharmaceuticals, Inc. can expect further growth in CF, with more than 30,000 CF patients who could benefit from the triple combination, but who are not yet receiving treatment.
Vertex Pharmaceuticals Investor Tip
- Vertex Pharmaceuticals, Inc. trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol VRTX. Vertex Pharmaceuticals, Inc. forms part of both the NASDAQ-100 and the S&P 500
- An analysis on the market performance for Vertex Pharmaceuticals, Inc. for the second quarter of 2025, having ended in June, indicated revenues of $1.79 billion (26.1 billion ZAR), showing an increase of 18% when compared to the second quarter of 2025.
- Vertex Pharmaceuticals, Inc. raised full-year 2025 guidance for product revenues to $7.2 billion (105.1 billion ZAR).
- The third phase study of next-in-class triple combination for CF is set to start in the second half of 2025, with multiple additional clinical milestones across the product portfolio expected in the next 6 to 9 months.
- Vertex Pharmaceuticals, Inc. has made immense progress in its pipeline programs during the first quarter of the year, with advancements moving quickly as five programs are already in the mid- or late-stage clinical trials.
- Non-GAAP income recorded for the quarter was just over $1 billion (14.6 billion ZAR), which shows an 18% increase from the same quarter in 2025, in which Vertex Pharmaceuticals, Inc. achieved $874 million (12.7 billion ZAR).
- The GAAP net diluted income per share was $0.26 (3.80 ZAR), which is significantly lower than the $3.18 for the second quarter of 2025 while the Non-GAAP net diluted income per share is $3.11 (45.42 ZAR), showing a 19% increase from the $2.61 (38.12 ZAR) for 2025.
- The increase in product revenues is attributable to the uptake of KAFTRIO in Europe along with continued performance from TRIKAFTA in the United States. The GAAP net income decreased due to the $900 million (13.1 billion ZAR) payment associated with the amendment to Vertex Pharmaceuticals, Inc.’s collaboration with CRISPR Therapeutics, recorded as GAAP research and development expenses.
- Data from the analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.
Sector
Healthcare
Industry
Biotechnology
Sub industry
Pharmaceuticals and Biotherapeutics
Latest News
Vertex Pharmaceuticals: How to buy Vertex Pharmaceuticals Shares Online
Here are the steps you need to follow to buy Vertex Pharmaceuticals, Inc. shares with utmost confidence:
- Navigate to the AvaTrade website and select ‘Register’.
- Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
- As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
- Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
- From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘VRTX’ to buy/purchase shares.
- Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.
Trading CFDs and Stocks with AvaTrade provides traders with the following benefits:
- Leverage of up to 1:20.
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools.
- Trades can be executed across multiple platforms.
More shares that can be purchased through AvaTrade, can be viewed here.
FAQ
Can I buy Vertex Pharmaceuticals, Inc. shares in South Africa?
Yes, you can.
How to buy Vertex Pharmaceuticals, Inc. shares?
By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.
What is the current share price?
By clicking on the link provided above, you can view the real-time Vertex Pharmaceuticals, Inc. share price on the platform.
Is Vertex Pharmaceuticals, Inc. a good share to buy?
Yes, it is. Vertex Pharmaceuticals, Inc. has shown increased and strong financial performance when compared to the same quarter in 2025.
Can I buy Vertex Pharmaceuticals, Inc. CFD through SA Shares?
Yes, you can.
Top 4 Brokers
